[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:
10.1177/1060028018797110[2] R Takei, et al. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol. 1999 Apr;79(4):447-54. DOI:
10.1254/jjp.79.447[3] Yasuhide Hori, et al. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. Cancer Prev Res (Phila). 2011 Jan;4(1):87-96. DOI:
10.1158/1940-6207.CAPR-10-0189[4] MASUMORI N. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia.[J]. Therapeutics and Clinical Risk Management, 2011, 7: 227-238. DOI:
10.2147/tcrm.s13883[5] IKUNOBU MURAMATSU Shigcru K Kyozo Yamanaka. Pharmacological Profile of the Novel α-Adrenoceptor Antagonist KT-611 (Naftopidil)[J]. Japanese journal of pharmacology, 1991, 55 3: Pages 391-398. DOI:
10.1016/s0021-5198(19)39941-x[6] HIDEKI KANDA. Naftopidil, a selective α-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest[J]. International Journal of Cancer, 2007, 122 2: 444-451. DOI:
10.1002/ijc.23095
